紫杉醇联合不同铂类同步放化疗在晚期子宫颈癌中的应用  

Application of Paclitaxel Combined with Different Platinum Concurrent Chemoradiotherapy in Advanced Cervical Cancer

作　　者：孙敏 濮莲芳 张媛 SUN Min;PU Lianfang;ZHANG Yuan(Jiangnan University Affiliated Hospital,Wuxi 214000,China;不详)

机构地区：[1]江南大学附属医院,江苏无锡214000

出　　处：《中外医学研究》2023年第23期37-41,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨紫杉醇联合不同铂类同步放化疗在晚期子宫颈癌中的应用。方法:选取2015年1月-2020年1月江南大学附属医院收治的108例晚期子宫颈癌患者为研究对象。根据随机数表法将其分为奥沙利铂(Oxaliplatin,L-OHP)组和顺铂(Cisplatin,DDP)组,各54例。DDP组给予紫杉醇联合DDP同步放化疗,L-OHP组给予紫杉醇联合L-OHP同步放化疗。比较两组临床疗效,治疗前后肿瘤标志物、免疫功能,毒性反应及生存情况。结果:两组临床疗效及总有效率比较,差异无统计学意义(P>0.05)。治疗后,两组细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)、鳞状细胞癌抗原(squamous cell carcinoma antigen,SCC-Ag)水平较治疗前显著下降,差异有统计学意义(P<0.05),两组CYFRA21-1、SCC-Ag水平比较,差异无统计学意义(P>0.05)。治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)较治疗前显著降低,CD8^(+)较治疗前显著升高,差异有统计学意义(P<0.05),两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05)。L-OHP组脱发、骨髓抑制发生率均显著低于DDP组,差异有统计学意义(P<0.05)。两组生存率比较,差异无统计学意义(χ^(2)=0.177,P=0.674)。结论:紫杉醇联合L-OHP同步放化疗与紫杉醇联合DDP同步放化疗在晚期子宫颈癌中的效果相似,均能有效降低肿瘤标志物水平,但L-OHP脱发、骨髓抑制发生率要低于DDP。Objective:To investigate the application of Paclitaxel combined with different platinum concurrent chemoradiotherapy in advanced cervical cancer.Method:A total of 108 patients with advanced cervical cancer admitted to the Jiangnan University Affiliated Hospital from January 2015 to January 2020 were selected as the study objects.They were divided into Oxaliplatin(L-OHP)group and Cisplatin(DDP)group according to random number table method,with 54 cases in each group.DDP group was given Paclitaxel combined with DDP concurrent chemoradiotherapy,L-OHP group was given Paclitaxel combined with L-OHP concurrent chemoradiotherapy.The clinical efficacy,tumor markers,immune function before and after treatment,toxicity reaction and survival condition of the two groups were compared.Result:There were no significant differences in clinical efficacy and total effective rate between the two groups(P>0.05).After treatment,the levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and squamous cell carcinoma antigen(SCC-Ag)in the two groups were significantly lower than those before treatment,the differences were statistically significant(P<0.05),and there were no significant differences in CYFRA21-1,SCC-Ag between the two groups(P>0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)in both groups were significantly lower than those before treatment,and CD8^(+)were significantly higher than those before treatment,the differences were statistically significant(P<0.05),while there were no statistical significances in CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups(P>0.05).The incidence of alopecia and myelosuppression in L-OHP group was significantly lower than that in DDP group,the differences were statistically significant(P<0.05).There was no significant difference in survival rate between the two groups(χ^(2)=0.177,P=0.674).Conclusion:The efficacy of Paclitaxel combined with L-OHP concurrent chemoradiotherapy is similar to that of Paclitaxel combined with DDP concurrent chemoradiotherapy in advanced cervical cancer,both

关 键 词：子宫颈癌 紫杉醇 同步放化疗 奥沙利铂 顺铂 

分 类 号：R737.33[医药卫生—肿瘤]